FindTrial
Sign In

Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study

Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107677
Enrollment
Unknown
Registered
2025-08-18
Start date
2025-08-31
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic neuroendocrine tumor

Interventions

Early-onset pancreatic neuroendocrine tumors group:None
Late-onset pancreatic neuroendocrine tumors group:None

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. 18 years or older; 2. Histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Exclusion criteria

Exclusion criteria: 1. Pancreatic neuroendocrine carcinoma; 2. Incomplete pathological data; 3. Received antitumor treatment prior to presentation; 4. With other malignanies or malignant history.

Design outcomes

Primary

MeasureTime frame
Tumor stage;Tumor grade;Total Cholesterol;High-Density Lipoprotein Cholesterol;Low-Density Lipoprotein Cholesterol;Triglyceride;Overall survival;—

Secondary

MeasureTime frame
Tumor size;Tumor function;Tumor location;Tumor number;Body Mass Index;Waist Circumference;Fasting Plasma Glucose;Disease-specific survival;Progression-free survival;Disease-free survival;—

Countries

China

Contacts

Public ContactHanxiang Zhan

Qilu Hospital of Shandong University

zhanhanxiang@hotmail.com+86 185 6008 5156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026